Last reviewed · How we verify
Single Dose MPCs Injection
At a glance
| Generic name | Single Dose MPCs Injection |
|---|---|
| Also known as | Direct MPCs Lumbar Disc Injection., Stem Cells |
| Sponsor | Mesoblast, Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle (PHASE1, PHASE2)
- Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain (PHASE2)
- Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Single Dose MPCs Injection CI brief — competitive landscape report
- Single Dose MPCs Injection updates RSS · CI watch RSS
- Mesoblast, Ltd. portfolio CI